Recent years have seen dramatic advances in deciphering the molecular pathogenesis of chronic myeloid leukemia (CML). This has resulted in the rapid development of many BCR-ABL1-specific tyrosine kinase inhibitors (TKI) which have improved 10-year survival to more than 80%. In this paper we focus on some future directions for CML biology and therapy.
Carella A.M., Goldman J.M., Martinelli G., Melo J.V., Perrotti D. (2011). Chronic myeloid leukemia: the basis of treatment for tomorrow. HAEMATOLOGICA, 96(12), 1737-1739 [10.3324/haematol.2011.052571].
Chronic myeloid leukemia: the basis of treatment for tomorrow.
MARTINELLI, GIOVANNI;
2011
Abstract
Recent years have seen dramatic advances in deciphering the molecular pathogenesis of chronic myeloid leukemia (CML). This has resulted in the rapid development of many BCR-ABL1-specific tyrosine kinase inhibitors (TKI) which have improved 10-year survival to more than 80%. In this paper we focus on some future directions for CML biology and therapy.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
